Sign in
CompletedNo phase

Neurocognitive Impairment in Patients With COVID-19

Key facts

Who runs it
University of Rostock
Where
Germany1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
118 people enrolled
Started
15 Apr 2020
Ended
31 Dec 2023
Type of study
Observational, 4 groups
Record updated
29 January 2024

Who can take part

Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • adult patients of every age
  • admission to hospital with suspected COVID-19 disease
  • confirmed SARS-CoV-2 infection within 48 hours after admission

Who cannot take part

  • other acute central nervous system diseases (e.g. meningoencephalitis, intracerebral ischemia or hemorrhage)
  • confirmed SARS-CoV-2 infection later than 48 hours after hospital admission
  • transferral from another hospital
  • participation in another interventional study
  • no written informed consent from patient or legal representative

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Delirium and acute neurocognitive impairment are increasingly observed in adult and pediatric patients with COVID-19. Prospective clinical studies combining clinical and laboratory examinations including specific biomarkers of neuroaxonal injury were not performed for COVID-19. The value of biomarkers of neuroaxonal injury was proven in preliminary studies. These biomarkers could thus contribute to the systematic detection of neurocognitive impairment in patients with COVID-19. Due to worldwide increasing numbers of hospitalized patients with COVID-19, biomarkers of neuroaxonal injury are highly valuable to detect and monitor cognitive impairment, especially with regard to limited resources available to perform time-consuming brain imaging.

Read full original descriptionShow less

Biomarkers of neuroaxonal injury are therefore not only of great interest to detect neurocognitive impairment but also to quantify the severity of brain injury in patients with COVID-19.

The 4 groups in the trial

  • NCoV-A-COVID

    * adult patients of every age * admission to hospital with suspected COVID-19 disease * confirmed SARS-CoV-2 infection within 48 hours after admission

  • NCoV-A-CONTROL

    * adult patients of every age * admission to hospital with suspected COVID-19 disease * exclusion of SARS-CoV-2 infection within 48 hours after admission

  • NCoV-P-COVID

    * pediatric patients * admission to hospital with suspected COVID-19 disease * confirmed SARS-CoV-2 infection within 48 hours after admission

  • NCoV-P-CONTROL

    * pediatric patient * admission to hospital with suspected COVID-19 disease * exclusion of SARS-CoV-2 infection within 48 hours after admission

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Biomarker-guided Assessment of Neurocognitive Impairment in Patients With COVID-19 - a Multicenter Case-control Study
Publications
Record updated
29 January 2024